We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 14 for:    Recruiting, Not yet recruiting, Available Studies | "Sciatica"

Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica

This study is currently recruiting participants.
Verified September 2017 by Eisenberg Elon MD, Rambam Health Care Campus
Sponsor:
ClinicalTrials.gov Identifier:
NCT01914042
First Posted: August 1, 2013
Last Update Posted: September 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Eisenberg Elon MD, Rambam Health Care Campus
  Purpose
Clinical, psychophysical, behavioral or genetic factor will predict the response to opioid treatment in patients with chronic neuropathic pain.

Condition Intervention Phase
Neuropathic Pain Drug: Morphine Drug: Milnacipran Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Prediction of Inter-individual Differences in the Response to Morphine by Psychophysical Assessment of Pain Enhancing and Inhibiting Mechanisms in Patients With Chronic Neuropathic Pain

Resource links provided by NLM:


Further study details as provided by Eisenberg Elon MD, Rambam Health Care Campus:

Primary Outcome Measures:
  • Neuropathic pain intensity (NPS) [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Heat pain intensity in a remote area (Opioid induced hyperalgesia) [ Time Frame: 1 month ]
    Heat pain sensitivity will be determined by the use of VAS units (0-100). We'll measure the intensity of pain in response to application of brief experimental heat pain.

  • The McGill Pain Questionnaire [ Time Frame: At baseline and at the end of 4-week treatment period ]
    Will be completed before and after treatment

  • Assessment of Adverse events [ Time Frame: Ongoing throughout the entire study period, an expected average of 4 weeks. ]

    A list of possible side effects from the administered drugs has been prepared and will be completed at all scheduled visits.

    In addition, patients will record AEs on daily basis. If needed patients can call and report adverse events by phone.



Estimated Enrollment: 150
Study Start Date: July 2013
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Morphine
Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
Drug: Morphine
Active Comparator: Milnacipran
Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
Drug: Milnacipran

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with moderate to severe chronic neuropathic pain or patients with radiculitis between 18 and 75 years of age.
  2. Candidates for chronic opioid therapy for nonmalignant pain as determined by treating physician.
  3. Patients treated with non-opioid analgetics, anti- inflammatory drugs or low opioid dosage (< 30 mg of oral morphine-equivalents per day).
  4. Ability to understand the purpose and instructions of the study and to sign an informed consent.

    Exclusion Criteria:

1.Diabetic Neuropathy 2.Pain in upper limbs 3.Receiving anti- depressants and/or anticonvulsants 4.Pregnant women 5.Inability to comply with study protocol. 6.Allergy to Opioids 7.A diagnosis of Raynaud's Syndrome 8.History of substance abuse

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01914042


Contacts
Contact: Elon Eisenberg, MD 972 4 8542880 e_eisenberg@rambam.health.gov.il

Locations
Israel
Rambam Health Care Campus Recruiting
Haifa, Israel, 31096
Contact: Elon Eisenberg, MD    972 4 8542880    e_eisenberg@rambam.health.gov.il   
Principal Investigator: Elon Eisenberg, MD         
Sponsors and Collaborators
Rambam Health Care Campus
  More Information

Responsible Party: Eisenberg Elon MD, Director, Pain Research Unit, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT01914042     History of Changes
Other Study ID Numbers: 143-10 RMB
First Submitted: July 22, 2013
First Posted: August 1, 2013
Last Update Posted: September 12, 2017
Last Verified: September 2017

Keywords provided by Eisenberg Elon MD, Rambam Health Care Campus:
Opioid induced hyperalgesia
Neuropathic pain
Opioids
Sciatica
Serotonin-norepinephrine reuptake inhibitor (SNRI)

Additional relevant MeSH terms:
Neuralgia
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Morphine
Norepinephrine
Milnacipran
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Sympathomimetics
Autonomic Agents
Vasoconstrictor Agents
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators